ClearNote Health raised $52 million in Series D financing, bringing total funding to more than $185 million. Founding investor Mattias Westman led the round with participation including Sandy Weill and ClearNote Health cofounder Stephen Quake. The San Diego-based company plans to use the proceeds for clinical studies, commercial expansion, continued product development, and broader global access for its Avantect early cancer detection tests and its Virtuoso epigenomic drug development platform. ClearNote said it recently presented performance data for an Avantect Pancreatic Cancer test, reporting 82.6% sensitivity for early detection. The funding also included leadership changes with the appointment of Kevin Keegan as president and chief operating officer, signaling an execution push across clinical validation and commercialization.